%A Hu Mengxue, Xu Bin, Yu Jinming, Song Qibin %T Advances of bifunctional anti-PD-L1/TGF-β fusion protein M7824 %0 Journal Article %D 2019 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2019.05.006 %P 281-284 %V 46 %N 5 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10634.shtml} %8 2019-05-08 %X With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data.